UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 5, 2007
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other
jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 995-2500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
ITEM 5.02. — DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
(a) Not applicable.
(b) On March 6, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) announced the March 5, 2007 departure of Walter Blättler, Ph.D., formerly the Executive Vice President, Science and Technology, from the Company in accordance with Section 2, paragraph (b)(ii)(C) of his employment agreement, which was filed with ImmunoGen’s Quarterly Report on Form 10-Q, for the period ended December 31, 2006.
A copy of the press release regarding the departure is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c), (d), and (e) Not applicable.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated March 6, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
|
Date: March 9, 2007 |
|
/s/ Daniel M. Junius |
|
|
|
|
|
|
|
|
|
|
|
Daniel M. Junius |
|
|
|
|
|
Executive Vice President and Chief Financial Officer |
|
|
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated March 6, 2007 |
|
|
|
|